| Psoriasis vulgaris
Zoryve Cream vs Tazorac
Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.Deep comparison between: Zoryve vs Tazorac with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTazorac has a higher rate of injection site reactions vs Zoryve based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tazorac but not Zoryve, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Zoryve
Tazorac
At A Glance
Topical
Daily
PDE4 inhibitor
Topical
Daily
Retinoid
Indications
- Psoriasis vulgaris
- Dermatitis, Atopic
- Psoriasis vulgaris
- Acne Vulgaris
Dosing
Psoriasis vulgaris Apply ZORYVE cream, 0.3%, to affected areas once daily in adult and pediatric patients 6 years of age and older.
Dermatitis, Atopic Apply ZORYVE cream, 0.15%, once daily for patients 6 years of age and older; apply ZORYVE cream, 0.05%, once daily for pediatric patients 2 to 5 years of age.
Psoriasis vulgaris Apply a thin film (2 mg/cm2) of 0.05% cream once daily in the evening to psoriatic lesions only; increase to 0.1% if tolerated and medically indicated.
Acne Vulgaris Apply a thin layer (2 mg/cm2) of 0.1% cream once daily in the evening to affected facial skin areas after gentle cleansing and drying.
Contraindications
- Moderate to severe liver impairment (Child-Pugh B or C)
- Pregnancy (retinoids may cause fetal harm)
- Known hypersensitivity to any component of TAZORAC Cream
Adverse Reactions
Most common (>=1%), Plaque Psoriasis Diarrhea, headache, insomnia, nausea, application site pain, upper respiratory tract infection, urinary tract infection
Most common (>=1%), Atopic Dermatitis Headache, nausea, application site pain, diarrhea, vomiting, upper respiratory tract infection, rhinitis, conjunctivitis
Most common (>=10%) Psoriasis: pruritus, erythema, burning; Acne: desquamation, dry skin, erythema, burning sensation
Serious Embryofetal toxicity, photosensitivity and risk of sunburn
Postmarketing Blister, dermatitis, urticaria, skin exfoliation, skin discoloration (hyperpigmentation or hypopigmentation), swelling at or near application sites, pain
Pharmacology
PDE4 inhibitor; roflumilast and its active metabolite (roflumilast N-oxide) inhibit PDE4, a major cyclic AMP-metabolizing enzyme, leading to accumulation of intracellular cyclic AMP.
Tazarotene is a retinoid prodrug converted by esterase hydrolysis to tazarotenic acid, which binds retinoic acid receptors RAR-beta and RAR-gamma with relative selectivity and may modify gene expression in psoriatic and acne-affected skin.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Zoryve
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
No coverage data available for Tazorac.
UnitedHealthcare
Zoryve
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (4/8)
No coverage data available for Tazorac.
Humana
Zoryve
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
No coverage data available for Tazorac.
Coverage data sourced from MMIT. Updated monthly.
Savings
$0
Arcutis Cares Patient Assistance: ZoryveCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Tazorac.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ZoryveView full Zoryve profile
TazoracView full Tazorac profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.